| Protocol | Title |
|---|---|
| 10403 | An Intergroup Phase II Clinical Trial for Adolescents and Young
Adults with Untreated Acute Lymphoblastic Leukemia (ALL)
Activation Date: 14-may-2008 |
| 10404 | A Genetic, Risk-Stratified Randomized Phase II Study of Four
Fludarabine/Antibody Combinations for Patients with Symptomatic,
Previously Untreated Chronic Lymphocytic Leukemia
Activation Date: 14-may-2008 |
| CALGB10501 | A Phase III Intergroup CLL Study of Asymptomatic Patients with
Untreated Chronic Lymphocytic Leukemia Randomized To Early
Intervention Versus Observation with Later Treatment in the High risk
Genetic Subset with IGVh Unmutated Disease
Activation Date: 22-jan-2008 |
| CALGB10603 | A Phase III Randomized, Double-Blind Study of Induction
(Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine)
Chemotherapy + Midostaurin (PKC412) or Placebo in Newly Diagnosed
Patients < 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia
(AML)
Activation Date: 22-apr-2008 |
| E1902 | A Phase II Study of Reduced Intensity Allogeneic Stem Cell Transplant
for the Treatment of Myelodysplastic Syndromes
Activation Date: 18-may-2005 Suspended: 23-sep-2009 ECOG Participants(requires Adobe Acrobat) |
| E1904 | A Phase II Study of MOAD (Methotrexate, Vincristine, L-asparaginase,
and Dexamethasone) with Subcutaneous Campath (NSC 715969) for Adults
with Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)
Activation Date: 29-jun-2006 Suspended: 16-apr-2008 ECOG Participants(requires Adobe Acrobat) |
| E1905 | A Randomized Phase II Trial of Azacitidine with or without the
Histone Deacetylase Inhibitor Entinostat for the Treatment of
Myelodysplastic Syndrome,Chronic Myelomonocytic Leukemia (Dysplastic
Type), and Acute Myeloid Leukemia with Multilineage Dysplasia
Activation Date: 18-aug-2006 |
| E1906 | A Phase II Randomized Trial of Carboplatin and Topotecan;
Flavopiridol, Mitoxantrone and Cytosine Arabinoside; and Sirolimus,
Mitoxantrone, Etoposide and Cytosine Arabinoside for the Treatment of
Adults with Primary Refractory or Initial Relapse of Acute
Myelogenous Leukemia(AML) (Limited institution participation)
Activation Date: 16-oct-2008 |
| E2902 | A Phase III Randomized Study of Farnesyl Transferase Inhibitor
R115777 in Acute Myeloid Leukemia (AML) Patients in Second or
Subsequent Remission or Remission after Primary Induction Failure or
Patients over Age 60 in First Remission
Activation Date: 18-aug-2004 |
| E2903 | Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab (PCR)
Followed By Campath-1H For Previously Treated Relapsed or Refractory
Patients With Chronic Lymphocytic Leukemia
Activation Date: 16-dec-2004 ECOG Participants(requires Adobe Acrobat) |
| E2905 | Randomized Phase III Trial Comparing the Frequency of Major Erythroid
Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in
Combination with Epoetin Alfa (Procrit) in Subjects with Low- or
Intermediate-1 Risk MDS and Symptomatic Anemia
Activation Date: 29-jan-2009 |
| E3903 | Ancillary Laboratory Protocol for Collecting Diagnostic Material on
Patients Considered for ECOG Treatment Trials for Leukemia or Related
Hematologic Disorders
Activation Date: 08-jul-2004 ECOG Participants(requires Adobe Acrobat) |
| S0521 | A Randomized Trial of Maintenance Versus Observation For Patients
With Previously Untreated Low and Intermediate Risk Acute Promyelomic
Leukemia (APL), Phase III
Activation Date: 22-jan-2008 |
| S0535 | A Phase II Study of ATRA, Arsenic Trioxide, and Gemtuzumab Ozogamicin
in Patients with Previously Untreated High-Risk Acute Promyelocytic
Leukemia
Activation Date: 23-jun-2008 |
All contents copyright © 1998 Eastern Cooperative Oncology Group.
All rights reserved.
Revised: 11/24/09